Call to Action for Liver Associations to Advance Progress Towards Viral Hepatitis Elimination
Call to Action:
The time has come to simplify HCV testing and treatment. Accurate rapid HCV antibody screening and confirmatory viral load testing can be accomplished in a single clinical visit. Pan-genotypic direct-acting antivirals (DAAs) are available in fixed dose combinations with efficacy rates greater than 95% and minimal side effects. Together, these tools allow for simplification and scale-up of HCV treatment with cure of nearly all uncomplicated cases in 8-12 weeks.
To eliminate HCV by 2030, the AASLD, EASL, APASL and ALEH call for bold action, centered around a public health approach to define the burden of viral hepatitis, identify modes of transmission, develop and evaluate interventions, and assure widespread implementation to assure health equity for all populations. To achieve goals for hepatitis elimination, the evidence-based strategies for screening, diagnosis and cure, in line with HCV treatment guidelines from WHOi and the UN Political Declaration on Universal Health Coverage must be broadly implemented.